A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma

Summary

This will be a Phase 1 Open-Label, dose escalation of MT-0169 (an Engineered toxin body (ETB) in patients with relapsed or refractory multiple myeloma. MT-0169 is an investigational drug that recognizes and binds to the CD38 receptor, which may be found on the surface of multiple myeloma cancer cells. It delivers a dose of a modified toxin that kills these cells.

Timeline

Start

2020-02-05

Primary completion

2023-12-13

Completion

2023-12-13

Outcome

Outcome not reported

Stopped (Enrollment): “Sparse/no patient enrollment”

Drugs

Indications